Base de dados : MEDLINE_1966-1996
Pesquisa : B01.150.900.649.801.400.112.400.400 [Categoria DeCS]
Referências encontradas : 5836406 [refinar]
Mostrando: 1 .. 10   no formato [Longo]

página 1 de 583641 ir para página                         

  1 / 5836406 MEDLINE_1966-1996  
              next record last record
seleciona
para imprimir
Fotocópia
PMID:17636697
Autor:Airey M; Bennett C; Nicolucci A; Williams R
Título:WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD002182
Fonte:Cochrane Database Syst Rev; (1):CD002182, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Diabetic peripheral neuropathy is a common complication of diabetes mellitus. OBJECTIVES: To assess the efficacy of aldose reductase inhibitors in the prevention, reversal or delay in the progression of diabetic peripheral neuropathy. SEARCH STRATEGY: The Cochrane Diabetes Group's database was searched and the citation lists of identified trials and previous reviews checked. Investigators identified as active in the field were approached for overlooked studies. SELECTION CRITERIA: Randomised controlled trials of aldose reductase inhibitors versus placebo, no treatment or other treatment in diabetic patients with or without clinical neuropathy. DATA COLLECTION AND ANALYSIS: Nerve conduction velocity was the only end point measured in all trials. Treatment effect was evaluated in terms of nerve conduction velocity mean difference in median and peroneal motor and median and sural sensory nerves. MAIN RESULTS: 19 trials, testing 4 different aldose reductase inhibitors for between 4 to 208 weeks duration (median 24 weeks), met the inclusion criteria for the meta-analysis. A small but statistically significant reduction in decline of median and peroneal motor nerve conduction velocities was present in the treated group when compared to the control group (weighted mean 0.66 m/s 95% CI 0.18-1.14 m/s and 0.53 m/s 95% CI 0.02-1.04m/s respectively). No clear benefit of aldose reductase inhibitor treatment was observed in either of the sensory nerves. AUTHORS' CONCLUSIONS: Although aldose reductase inhibitor treatment has been demonstrated to diminish the reduction in motor nerve conduction velocity, the clinical relevance of such a change in this outcome measure is uncertain. There was no effect in terms of this outcome measure in the smaller sensory fibres, degeneration of which is primarily responsible for the most common neuropathic syndrome associated with diabetes, that of severe pain and loss of sensation in the extremity leading in some cases to ulceration and eventual amputation.
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Enzyme Inhibitors); EC 1.1.1.21 (Aldehyde Reductase)


  2 / 5836406 MEDLINE_1966-1996  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PMID:17636615
Autor:Koudstaal PJ
Endereço:University Hospital Rotterdam, Department of Neurology, 40 Dr Molewaterplein, Rotterdam, Netherlands, 3015 GD. p.j.koudstaal@erasmusmc.nl
Título:WITHDRAWN: Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000186
Fonte:Cochrane Database Syst Rev; (1):CD000186, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: People with nonrheumatic atrial fibrillation who have had a transient ischemic attack or minor ischemic stroke are at risk of recurrent stroke. OBJECTIVES: The objective of this review was to assess the effect of antiplatelet therapy for secondary prevention in people with nonrheumatic atrial fibrillation and a previous transient ischaemic attack or ischaemic stroke. SEARCH STRATEGY: The reviewer searched the Cochrane Stroke Group trials register and contacted trialists. SELECTION CRITERIA: Randomised trials comparing an antiplatelet agent with placebo or open control in people with nonrheumatic atrial fibrillation and a previous transient ischaemic attack or minor ischaemic stroke. DATA COLLECTION AND ANALYSIS: One reviewer extracted the data. MAIN RESULTS: One trial was included, in which 300 milligrams of aspirin per day was compared with placebo. This review includes 404 aspirin-treated patients and 378 placebo patients in total. The mean follow-up was 2.3 years. No difference was shown between aspirin and placebo in the annual rate of all vascular events, including vascular death, recurrent stroke (ischaemic or haemorrhagic), myocardial infarction, and systemic embolism. The odds ratio was 0.84, 95% confidence interval 0.63 to 1.14, or 15% of those receiving aspirin versus 19% for those given placebo. Aspirin may prevent 40 vascular events (of all types) per 1000 patients treated for one year. There was a non-significant reduction in the risk of recurrent stroke from 12% to 10% per year (odds ratio 0.89, 95% confidence interval 0.64 to 1.24). The incidence of major bleeding events, requiring hospitalisation, blood transfusion or surgical treatment, was low (0.9% per year for aspirin versus 0.7% for placebo). AUTHORS' CONCLUSIONS: Aspirin may reduce the risk of vascular events in people with nonrheumatic atrial fibrillation, but the effect shown in the single trial was not statistically significant.
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Platelet Aggregation Inhibitors)


  3 / 5836406 MEDLINE_1966-1996  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PMID:17636606
Autor:Vandekerckhove P; Lilford R; Vail A; Hughes E
Endereço:St Mary's Hospital, IOW Healthcare NHS Trust, Parkhurst Road, Newport, Isle of Wight, UK PO30 5TG. Patrick.Vandekerckhove@iow.nhs.uk
Título:WITHDRAWN: Kinin-enhancing drugs for unexplained subfertility in men.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000153
Fonte:Cochrane Database Syst Rev; (4):CD000153, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology) of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility. One suggested treatment for idiopathic oligo- and/or asthenospermia is the administration of kallikrein (kallidinogenase), a kinin-releasing enzyme (or kininogenase). Although the kinin system may also be involved in the regulation of spermatogenesis in vivo, a clear mechanism of action is missing. Multiple suggestions on how an increase in kinin levels in the genital tract influences spermatogenesis at the testicular levels have been made by various authors. OBJECTIVES: To determine whether treatment of the male with drugs enhancing kinin levles increases pregnancy rates among couples where failure to conceive has been attributed to idiopathic oligo- and/or asthenospermia. Effects on sperm parameters and sex hormones were studied as secondary outcomes. SEARCH STRATEGY: The Cochrane Subfertility Review Group specialised register of controlled trials was searched. SELECTION CRITERIA: SIxteen RCTs on the therapeutic use of androgens (clomiphene citrate or tamoxifen) in subfertile men were identified. Six trials were excluded. DATA COLLECTION AND ANALYSIS: All data were extracted by the first author. Unclear issues were resolved by consensus with the senior author (RL). Data was combined for meta-analysis using Peto odds ratios for dichotomous data or weighted mean difference for continuous data. MAIN RESULTS: X AUTHORS' CONCLUSIONS: This review does not provide conclusive proof of effectiveness. The benefit on pregnancy rates suggested by observational studies and low quality controlled trials is not confirmed by more rigorous trials. A modest effect on sperm motility is technically possible but was again not confirmed in the better quality trials. The clinical significance of a modest increase in sperm motility is uncertain. Untill effectiveness is proven, kallikrein should only be used in the context of clinical trials.
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Fertility Agents, Male); EC 3.4.21.- (Kallikreins)


  4 / 5836406 MEDLINE_1966-1996  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PMID:17636605
Autor:Vandekerckhove P; Lilford R; Vail A; Hughes E
Endereço:St Mary's Hospital, IOW Healthcare NHS Trust, Parkhurst Road, Newport, Isle of Wight, UK PO30 5TG. Patrick.Vandekerckhove@iow.nhs.uk
Título:WITHDRAWN: Bromocriptine for idiopathic oligo/asthenospermia.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000152
Fonte:Cochrane Database Syst Rev; (4):CD000152, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology)of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility.Whilst bromocriptine treatment for reducing prolactin levels in hyperprolactinaemic males (as in females), and, in the treatment of hypogonadotropic hypogonadism with hyperprolactinaemia, is beneficial, it has also been used for oligospermic men in the absence of any endocrinopathy. Prolactin may play a direct role in spermatogenesis and hormone production. It has also been claimed that in oligospermic men with normal gonadotrophins mean prolactin levels are higher and that hyperprolactinaemia is more common compared to fertile men. It has been proposed that the administration of bromocriptine under these circumstances might counteract a prolactin-induced block on the action of gonadotrophins on the testicles and, subsequently, that the reduction in prolactin levels might lead to an improvement in semen parameters and fertility. Although it is not licensed for use in male infertility, bromocriptine has been used for normogonadotrophic individuals with oligospermia and normal or slightly elevated prolactin levels. This review considers the available evidence of the effect of bromocriptine therapy for normoprolactinaemic males with idiopathic oligo and/or asthenospermia. OBJECTIVES: The objective of this review was to assess the effects of bromocriptine on pregnancy rates among couples where subfertility has been attributed to idiopathic oligo- and/or asthenospermia. SEARCH STRATEGY: The Cochrane Subfertility Review Group specialised register of controlled trials was searched[quot ]. SELECTION CRITERIA: Randomised trials of oral bromocriptine versus placebo or no treatment for couples with subfertility attributed to male factor. DATA COLLECTION AND ANALYSIS: Data were extracted by one reviewer and any disagreements were resolved by discussion with other reviewers. MAIN RESULTS: Four studies were included. The method of randomisation was not specified in any of the trials, which were all of crossover design. Compared with placebo, bromocriptine was associated with a significant reduction in serum prolactin levels (weighted mean difference -195.3 micro international units per litre, 95% confidence interval -276.5 to -114). No effects on sperm parameters were seen. There was also no effect on pregnancy rates observed between bromocriptine and placebo (0.70 odds ratio, 95% confidence interval 0.15 to 3.24). AUTHORS' CONCLUSIONS: Bromocriptine appears to reduce prolactin levels in subfertile men with normal gonadotrophic function. There is not enough evidence to show that bromocriptine is helpful in improving fertility.[This abstract was prepared centrally.].
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Hormone Antagonists); 25614-03-3 (Bromocriptine); 9002-62-4 (Prolactin)


  5 / 5836406 MEDLINE_1966-1996  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PMID:17636604
Autor:Vandekerckhove P; Lilford R; Vail A; Hughes E
Endereço:St Mary's Hospital, IOW Healthcare NHS Trust, Parkhurst Road, Newport, Isle of Wight, UK PO30 5TG. Patrick.Vandekerckhove@iow.nhs.uk
Título:WITHDRAWN: Clomiphene or tamoxifen for idiopathic oligo/asthenospermia.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000151
Fonte:Cochrane Database Syst Rev; (4):CD000151, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology) of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility.The administration of anti-oestrogens is a common treatment because anti oestrogens interfere with the normal negative feedback of sex steroids at hypothalamic and pituitary levels in order to increase endogenous gonadotropin-releasing hormone secretion from the hypothalamus and FSH and LH secretion directly from the pituitary. In turn, FSH and LH stimulate Leydig cells in the testes, and this has been claimed to lead to increased local testosterone production, thereby boosting spermatogenesis with a possible improvement in fertility. There may also be a direct effect of anti-oestrogens on testicular spermatogenesis or steroidogenesis. This review considers the available evidence of the effect of both Clomiphene citrate and tamoxifen, both of which have a predominant anti-oestrogenic effect, for idiopathic oligo and/or asthenospermia. OBJECTIVES: The objective was to assess the effects of treating subfertile men with anti-oestrogens (clomiphene or tamoxifen) on pregnancy rates among couples where subfertility has been attributed to idiopathic oligo- and/or asthenospermia. SEARCH STRATEGY: The Cochrane Subfertility Review Group specialised register of controlled trials was searched[quot ]. SELECTION CRITERIA: Randomised trials of anti-oestrogen therapy for 3 months or more compared to placebo or no placebo for subfertile males among couples where subfertility is attributed to male factor. DATA COLLECTION AND ANALYSIS: Data were extracted independently by two reviewers. Any differences were resolved with a third reviewer. MAIN RESULTS: Ten studies involving 738 men were included. Five of the trials did not specify method of randomisation. Anti-oestrogens had a positive effect on endocrinal outcomes, such as serum testosterone levels. In trials with secure randomisation there was no difference in the pregnancy rate between the anti-oestrogen groups and the control groups (odds ratio 1.26, 95% confidence interval 0.99 to 1.56). The overall pregnancy rate for these five trials was 15.4% compared to the spontaneous rate of 12.5% in the control groups. These odds increased to 1.56 (95% confidence interval 0.99 to 2.19) when all 10 trials were included, but this result is likely to be artificially inflated. AUTHORS' CONCLUSIONS: Anti-oestrogens appear to have a beneficial effect on endocrinal outcomes, but there is not enough evidence to evaluate the use of anti-oestrogens for increasing the fertility of males with idiopathic oligo-asthenospermia.[This abstract was prepared centrally.].
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:10540-29-1 (Tamoxifen); 911-45-5 (Clomiphene)


  6 / 5836406 MEDLINE_1966-1996  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PMID:17636603
Autor:Vandekerckhove P; Lilford R; Vail A; Hughes E
Endereço:St Mary's Hospital, IOW Healthcare NHS Trust, Parkhurst Road, Newport, Isle of Wight, UK, PO30 5TG. Patrick.Vandekerckhove@iow.nhs.uk
Título:WITHDRAWN: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000150
Fonte:Cochrane Database Syst Rev; (4):CD000150, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology) of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility.Androgens have been suggested as a treatment because its binding proteins maintain a maintain a high intratesticular level testosterone essential for spermatogenesis and because the epididymis and seminal vesicles affect the seminal constitution and sperm motility and are also androgen-dependent. However exogenous testosterone was found to exert negative feedback on the pituitary-gonadal axis and thereby to suppress FSH and LH secretion. Spermatogenesis was thus adversely affected. Nevertheless androgens are used for the treatment of male infertility either for a putative direct [quot ]stimulatory[quot ] or [quot ]rebound[quot ] therapy. The stimulatory androgens used are mesterolone and testosterone undecanoate which, it is postulated, in a form and dosage that does not influence pituitary gonadotrophin secretion, either have a direct stimulatory effect on spermatogenesis or influence sperm transport and maturation though an effect on the epididymis, ductus deferens and seminal vesicles. Other androgens have been used to produce a rebound effect. These androgens are administered to suppress gonadotrophin secretion and spermatogenesis. After androgen therapy is discontinued there is a surge of FSH and LH and spermatogenesis is recommenced. Because of their different proposed mechanisms of action, stimulatory and rebound androgen therapy are analysed separately in the comparisons. This review considers the available evidence of the effect of androgens for idiopathic oligo and/or asthenospermia. OBJECTIVES: The objective of this review was to assess the effect of androgen treatment of men among couples where failure to conceive has been attributed to idiopathic oligo- and/or asthenospermia. SEARCH STRATEGY: The Cochrane Subfertility Review Group specialised register of controlled trials was searched[quot ]. SELECTION CRITERIA: Randomised trials of mesterolone or testosterone undecanoate versus placebo or no treatment (stimulatory therapy), or testosterone enanthate or testosterone undecanoate versus placebo or no treatment (rebound therapy) in couples where subfertility is attributed to male factor. DATA COLLECTION AND ANALYSIS: Eligibility and trial quality were assessed. MAIN RESULTS: Eleven trials involving 930 patients were included. For stimulatory therapy, androgens had little effect on endocrinal outcomes and sperm parameters. The rate of pregnancy after androgens with stimulatory effect compared to no treatment or placebo was also similar (odds ratio 1.10, 95% confidence interval 0.75 to 1.61). In rebound therapy, no difference was found in sperm parameters. The pregnancy rate after androgens with rebound effect also showed no difference compared to no treatment or placebo (odds ratio 1.60, 95% confidence interval 0.42 to 6.16). Adverse effects such as headaches and exanthema were reported. AUTHORS' CONCLUSIONS: There is not enough evidence to evaluate the use of androgens for male subfertility.[This abstract has been prepared centrally.].
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Androgens); 1424-00-6 (Mesterolone); 58-22-0 (Testosterone)


  7 / 5836406 MEDLINE_1966-1996  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PMID:17636602
Autor:Kramer MS
Endereço:McGill University, Faculty of Medicine, 1020 Pine Avenue West, Montreal, Quebec, Canada H3A 1A2. michael.kramer@mcgill.ca
Título:WITHDRAWN: Nutritional advice in pregnancy.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000149
Fonte:Cochrane Database Syst Rev; (4):CD000149, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Background pending. OBJECTIVES: To assess the effects of advising pregnant women to increase their energy and protein intakes on those intakes, on gestational weight gain, and on the outcome of pregnancy. SEARCH STRATEGY: The register of clinical trials maintained and updated by the Cochrane Pregnancy and Childbirth Group. Date of last search: October 2001. SELECTION CRITERIA: All acceptably controlled comparisons of nutritional advice, whether administered on a one-to-one basis or to groups of women. DATA COLLECTION AND ANALYSIS: Data were extracted by the author from published reports, and supplemented by additional information from trialists contacted by the author. MAIN RESULTS: Four trials involving 1108 women were included. Advice to increase energy and protein intakes seems to be successful in achieving those goals, but the increases are lower than those reported in trials of actual protein/energy supplementation. Data concerning effects on pregnancy outcome are available only from one trial, and, given the fact that its analysis was based on individual women despite randomization by clinic, the calculated confidence intervals are undoubtedly too narrow. Moreover, the 'significant' reduction in preterm birth associated with advice is not consistent with the total absence of effect on mean gestational age. One trial found no reduction in the incidence of pre-eclampsia. No data have been reported on potential adverse effects that might accompany increased fetal size, such as an increased risk of prolonged labour or Caesarean section. AUTHORS' CONCLUSIONS: Nutritional advice appears effective in increasing pregnant women's energy and protein intakes, but the implications for fetal, infant, or maternal health cannot be judged from the available trials. Given the rather modest health benefits demonstrated with actual protein/energy supplementation (see the Cochrane review of 'Balanced protein/energy supplementation in pregnancy'), however, the provision of such advice is unlikely to be of major importance.
Tipo de publicação: JOURNAL ARTICLE; REVIEW


  8 / 5836406 MEDLINE_1966-1996  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PMID:17636599
Autor:Kramer MS
Endereço:McGill University, Faculty of Medicine, 1020 Pine Avenue West, Montreal, Quebec, Canada, H3A 1A2. michael.kramer@mcgill.ca
Título:WITHDRAWN: Maternal antigen avoidance during lactation for preventing atopic disease in infants of women at high risk.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000132
Fonte:Cochrane Database Syst Rev; (4):CD000132, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Background pending. OBJECTIVES: To assess the effects of prescribing an antigen avoidance diet during lactation on the nutritional status of the mother and newborn and on the development of atopic disease in the child. The main focus is on women whose infants are at high risk for developing an atopic condition, based on a history of atopic disease in the mother, father, or a previous child. SEARCH STRATEGY: The register of clinical trials maintained and updated by the Cochrane Pregnancy and Childbirth Group. Date of last search: October 2001. SELECTION CRITERIA: All acceptably controlled comparisons of maternal antigen avoidance prescribed to lactating women at high risk, regardless of the degree of antigen avoidance (number of foods eliminated from the diet) or its duration. Trials of multimodal interventions that include manipulation of the infant's diet other than breast milk or of other nondietary aspects of the infant's environment (eg, exposure to inhaled allergens) have been excluded from the review. DATA COLLECTION AND ANALYSIS: Data were extracted by the author from published reports, and supplemented by additional information from trialists contacted by the author. MAIN RESULTS: Three trials involving 209 women were included.The combined data from the three available trials suggest a strong protective effect of maternal antigen avoidance on the incidence of atopic eczema during the child's first 12-18 months of life. Methodologic shortcomings in all three trials, however, argue for caution in applying these encouraging results. In particular, the high incidence of atopic eczema in the control groups of all three trials might be explained by nonblinding or de-blinding of the examining physicians. AUTHORS' CONCLUSIONS: Prescription of an antigen avoidance diet to a high-risk woman during lactation may substantially reduce her child's risk of developing atopic eczema, but better trials are needed.
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Dietary Proteins)


  9 / 5836406 MEDLINE_1966-1996  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PMID:17636598
Autor:Kramer MS
Endereço:McGill University, Faculty of Medicine, 1020 Pine Avenue West, Montreal, Quebec, Canada, H3A 1A2. michael.kramer@mcgill.ca
Título:WITHDRAWN: Maternal antigen avoidance during lactation for preventing atopic eczema in infants.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000131
Fonte:Cochrane Database Syst Rev; (4):CD000131, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Background pending. OBJECTIVES: To assess the effects of prescribing an antigen avoidance diet to lactating mothers of infants with atopic eczema on the severity of the eczema. SEARCH STRATEGY: The register of clinical trials maintained and updated by the Cochrane Pregnancy and Childbirth Group. Date of last search: October 2001. SELECTION CRITERIA: All acceptably controlled comparisons of maternal antigen avoidance prescribed to lactating mothers of infants with atopic eczema, regardless of the degree of antigen avoidance (number of foods eliminated from the diet) or its duration. DATA COLLECTION AND ANALYSIS: Data were extracted by the author from published reports, and supplemented by additional information from trialists contacted by the author. MAIN RESULTS: One trial involving 17 women was included. Based on this single small trial, maternal antigen avoidance was associated with a nonsignificant reduction in eczema severity. AUTHORS' CONCLUSIONS: The unimpressive results of this single trial should be interpreted with caution both because of its small size (n=17) and because the trial compared exposure to cow milk and egg with exposure to soya milk (soya can itself be allergenic). Maternal reports of changes in the severity of their breast-fed infants' eczema following ingestion of certain foods should be pursued by performing multiple (preferably double-blinded) challenges and dechallenges with the suspected foods.
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Dietary Proteins)


  10 / 5836406 MEDLINE_1966-1996  
              first record previous record
seleciona
para imprimir
Fotocópia
PMID:17636594
Autor:Kramer MS
Endereço:McGill University, Faculty of Medicine, 1020 Pine Avenue West, Montreal, Quebec, Canada, H3A 1A2. michael.kramer@mcgill.ca
Título:WITHDRAWN: Isocaloric balanced protein supplementation in pregnancy.
Comentários:Update Of:Cochrane Database Syst Rev. 2000;(2):CD000118
Fonte:Cochrane Database Syst Rev; (4):CD000118, 1996.
ISSN:1469-493X
País de publicação:England
Idioma:eng
Resumo:BACKGROUND: Background pending. OBJECTIVES: To assess the effects of providing pregnant women with isocaloric protein supplements (ie where the protein replaces an equal quantity of nonprotein energy) on gestational weight gain and on the outcome of pregnancy. SEARCH STRATEGY: The register of clinical trials maintained and updated by the Cochrane Pregnancy and Childbirth Group. Date of last search: October 2001. SELECTION CRITERIA: All acceptably controlled comparisons of isocaloric protein supplementation, as long as the protein content of the supplement was 'balanced', ie the protein provided <25% of its total energy content. DATA COLLECTION AND ANALYSIS: Data were extracted by the author from published reports, and supplemented by additional information from trialists contacted by the author. MAIN RESULTS: Three trials involving 966 women were included. The results suggest a decrease in maternal weight gain and mean birth weight and an increased risk of small-for-gestational-age (SGA) births with isocaloric protein supplementation, but no effect on mean gestational age or preterm birth. The data are insufficient to exclude potentially important effects on fetal or neonatal mortality, and maternal health outcomes have not been reported. AUTHORS' CONCLUSIONS: Balanced protein supplementation alone (ie without energy supplementation) is unlikely to be of benefit to pregnant women or their infants.
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Dietary Proteins)



página 1 de 583641 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   
Pesquisar por : Formulário livre    Formulário básico

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde